Who created Wegovy, and why does it matter for how you use it?

How did Novo Nordisk come to create Wegovy?

Novo Nordisk's path to Wegovy started not with obesity, but with type 2 diabetes. The company's researchers had long been studying GLP-1 (glucagon-like peptide-1) a hormone the gut releases in response to food. GLP-1 tells the pancreas to produce insulin, tells the stomach to slow down, and signals the brain's appetite centres that eating can stop. Novo Nordisk first developed liraglutide, an earlier GLP-1 medicine, and observed that patients consistently lost weight. That observation prompted a deliberate research programme into whether a more potent, longer-acting GLP-1 medicine could treat obesity directly.

Semaglutide was the result. It was engineered to bind more strongly to the GLP-1 receptor than the body's own hormone does, and to resist the enzymes that would normally break it down within minutes. The effect: a molecule that acts for a full week from a single injection. Wegovy, the higher-dose formulation of semaglutide developed specifically for weight management, was approved in the UK for that indication and carries a Black Triangle (▼) symbol, meaning it is subject to additional MHRA monitoring as clinical experience builds. More about how Wegovy works and who it is licensed for is covered in our full treatment overview.

The STEP 1 trial, published in the New England Journal of Medicine, showed that adults using semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight over 68 weeks. That figure comes from a trial structure where diet and activity support were built in from day one, not added as an afterthought.

Why does knowing Wegovy's origins help you eat better on it?

The GLP-1 mechanism that Novo Nordisk harnessed is not a simple appetite switch. It slows gastric emptying, meaning food stays in the stomach longer and fullness arrives sooner. It also acts on reward pathways in the brain, reducing the pull of highly palatable foods for many people. Both effects have direct consequences for what and how you should eat.

Because portions naturally shrink, getting enough protein and fibre from a smaller volume of food becomes genuinely important. Protein preserves muscle while weight falls; fibre supports gut health and steadies digestion. The practical guide to what to eat on Wegovy on this site covers the specifics, but the short version is: prioritise foods that do a lot of nutritional work in a small amount. Eggs, fish, legumes, leafy vegetables. Not because a list of rules says so, but because the biology of the medicine makes nutrient density more valuable than volume.

Alcohol and very high-fat meals can make GI side effects worse. Carbonated drinks add to the bloating some people experience. None of this is a moral judgement on food choices, it is the mechanism Novo Nordisk's scientists built, applied to a practical question. Whether ice cream fits into treatment is one of the questions our prescribers are asked most weeks; the answer depends on context and individual tolerance rather than a blanket rule.

What about supplements like creatine, does the Wegovy mechanism change anything?

One question that comes up as people try to protect muscle mass during weight loss is whether supplements commonly used in training are safe and useful on semaglutide. Creatine is the most frequent one. The short answer is that there is no evidence it interacts harmfully with semaglutide, but the detail matters. Because Wegovy slows gastric motility, the timing and tolerability of supplements can shift, and anyone using them should know what to look for.

The pages covering creatine and Wegovy together, and how creatine interacts with semaglutide more broadly, go into the evidence in full. The consistent thread across all of them is the same one running through Novo Nordisk's original trial design: the medicine works best when the lifestyle around it is thought through, not left to chance. Strength training and adequate protein work with the GLP-1 mechanism; they are not optional extras for people who want to avoid losing muscle alongside fat.

Peanut butter is another food people ask about specifically. It is calorie-dense, but it also carries protein and healthy fats. The answer for peanut butter on Wegovy is nuanced, portion size matters more than the food itself.

What does the Wegovy creator's ongoing research mean for UK patients today?

Novo Nordisk has not stood still since Wegovy's original approval. In the UK, the MHRA approved a higher 7.2mg maintenance dose of semaglutide, and on 14 April 2026 approved a dedicated single-dose 7.2mg Wegovy pen, a pre-set, auto-dosing injection with a built-in covered needle that locks after use. Trials at this dose reported average weight loss of around 20.7% over 72 weeks, approaching the results seen with the highest doses of tirzepatide. The starting dose remains 0.25mg regardless of which maintenance dose a prescriber aims for; titration still happens in monthly steps.

On 3 July 2026 the MHRA also granted conditional approval for semaglutide (Wegovy) to treat MASH (a form of fatty liver disease with moderate-to-advanced fibrosis) making it the first medicine approved for that specific indication in the UK. That approval is separate from weight management and is mentioned here only because it reflects the breadth of Novo Nordisk's continuing research into the same molecule.

For UK patients interested in private treatment, the cost of Wegovy in the UK varies by dose and provider. NHS access exists through specialist weight management services under NICE guidance, though waiting times vary significantly. The NHS medicines page for semaglutide covers the medicine's profile in detail. If you would like to explore whether Wegovy is clinically suitable for you through a private route, check your eligibility with our prescribers, your consultation is free, reviewed the same day by a named, GPhC-registered Independent Prescriber, and there is no obligation.